Adjust Font Size:

Press Releases

Advanced Cell Technology's Vice President of Research & Scientific Development to Present at the Life Science Institute's Symposium on Wednesday, May 9, 2007

Alameda, CA - May 8, 2007 Advanced Cell Technology's (OTCBB: ACTC) Vice President of Research and Scientific Development, Dr. Robert Lanza, will be highlighting the company's recent discovery that shows precursor cells, generated from human embryonic stem cells, have the ability to repair vascular damage in animals.

William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology stated, "We consider this to be the most exciting and significant scientific news that our company has ever produced. While the cells in this study were tested in animal models, we believe this breakthrough has the potential to benefit thousands of people suffering from vascular disease ACT is committed to moving this technology from the laboratory into the clinic. Further, we plan on filing an Investigational New Drug Application with the Food and Drug Administration for the first clinical application of these cells by the end of next year.”

Dr. Lanza's presentation will take place at The University of Michigan's International Life Sciences Institute in a symposium titled "Frontiers in Stem Cell Biology”. Following the symposium, the slides used in Dr. Lanza's presentation may be found on the company's website at "www.advancedcell.com/conference-presentations/":http://www.advancedcell.com/conference-presentations/.

About The International Life Sciences Institute

Founded in 1978, the International Life Sciences Institute (ILSI) is a nonprofit, worldwide foundation that seeks to improve the well being of the general public through the advancement of science. Its goal is to further the understanding of scientific issues relating to nutrition, food safety, toxicology, risk assessment, and the environment by bringing together scientists from academia, government, and industry.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.

For more information, please visit: "www.advancedcell.com":http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the annual report on Form 10-KSB for the fiscal year ending December 31, 2006.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Contacts

Media
Bill Douglass
The Investor Relations Group
(212) 825.3210

Investors
Joseph Kessler or James Carbonara
The Investor Relations Group
(212) 825-3210

Press Contact


Joseph Kessler
(212) 825-3210

Download PDF


05.09.07B.pdf

To view PDF Files, you must have Acrobat Reader.

Download Adobe Acrobat